[Tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma: real-world data from single institute experience].
Rinsho Ketsueki
; 63(10): 1363-1372, 2022.
Article
in Ja
| MEDLINE
| ID: mdl-36351641
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Lymphoma, Non-Hodgkin
/
Lymphoma, Large B-Cell, Diffuse
/
Receptors, Chimeric Antigen
Type of study:
Observational_studies
Limits:
Humans
Language:
Ja
Journal:
Rinsho Ketsueki
Year:
2022
Type:
Article